AURA

In May 2026, Aura Biosciences completed a public offering, raising approximately $299.4 million, which strengthened its balance sheet and extended its cash runway. On May 11, 2026, the company reported its first-quarter 2026 financial results. In June 2026, Aura Biosciences announced the completion of enrollment for its Phase 3 CoMpass trial in early choroidal melanoma, with topline data expected in the second half of 2027. On August 11, 2026, the company reported its second-quarter 2026 earnings, missing analysts' EPS expectations, and announced a strategic refocus on ocular oncology, including a 20% workforce reduction and C-suite overhaul, which is projected to extend its cash runway into the first half of 2029. Over the past 52 weeks, AURA stock has traded between $4.73 and $9.54, closing at $6.50 on October 8, 2026. The company is estimated to announce its next earnings between November 12 and November 13, 2026.